Research Progress of Vascular Neuro-Ophthalmic Emergencies

doi:10.3969/j.issn.1673-5765.2024.03.002

Abstract

Abstract: Neuro-ophthalmic emergency refers to the spectrum of neuro-ophthalmic clinical diseases that can seriously threaten patients’ vision or even endanger their lives if they are not diagnosed and treated in time, among which the neuro-ophthalmic emergency caused by vascular causes (vascular neuro-ophthalmic emergency) accounts for the vast majority. Due to the characteristics of interdisciplinary, patients with vascular neuro-ophthalmic emergency are often first referred to the department of ophthalmology or emergency, and the first doctors often have incomplete understanding of the disease, which is easy to lead to delayed diagnosis, misdiagnosis or missed diagnosis of such patients. When patients are referred to the department of neurology, if the neurologist’s diagnosis of the disease cannot be determined in time, it is easy to delay treatment. In this paper, the clinical manifestations, the examination methods and the treatment methods of the major diseases in the spectrum of vascular neuro-ophthalmic emergency were reviewed in order to provide the basis for the rapid diagnosis and accurate treatment of these diseases.

Key words: Neuro-ophthalmology; Vascular neuro-ophthalmology; Emergency

摘要： 神经眼科急症是指如果不能及时诊断和治疗，就会严重威胁患者视力甚至危及生命的神经眼科临床疾病谱，其中血管性原因所致的神经眼科急症（血管神经眼科急症）占绝大部分。由于交叉学科的特点，血管神经眼科急症患者多首诊于眼科或急诊，首诊医师往往对疾病认识不全面，易导致该类患者诊断滞后、误诊或漏诊；当患者转诊于神经科时，神经科医师如果对疾病的诊断不能及时确定，易导致治疗延迟。本文对血管神经眼科急症疾病谱主要疾病的临床表现、检查方法和治疗方法等方面进行综述，以期为该类疾病的快速诊断和精准治疗提供依据。

关键词: 神经眼科; 血管神经眼科; 急症

CLC Number:

LU Qingli, WU Songdi. Research Progress of Vascular Neuro-Ophthalmic Emergencies[J]. Chinese Journal of Stroke, 2024, 19(3): 256-265.

逯青丽, 吴松笛. 血管神经眼科急症的研究进展[J]. 中国卒中杂志, 2024, 19(3): 256-265.

References

[1] LEMOS J，EGGENBERGER E. Neuro-ophthalmological emergencies[J]. Neurohospitalist，2015，5（4）：223-233.
[2] HAYREH S S. Acute retinal arterial occlusive disorders[J]. Prog Retin Eye Res，2011，30（5）：359-394.
[3] 逯青丽，吴松笛. 视网膜动脉阻塞：“视网膜卒中”的认识与挑战[J]. 中国卒中杂志，2023，18（6）：712-719.
LU Q L，WU S D. Retinal artery occlusion：knowledge and challenge of“retinal stroke”[J]. Chin J Stroke，2023，18（6）：712-719.
[4] MAC GRORY B，SCHRAG M，BIOUSSE V，et al. Management of central retinal artery occlusion：a scientific statement from the American Heart Association
[J/OL]. Stroke，2021，52（6）：e282-e294[2023-11-30].
https://doi.org/10.1161/STR.0000000000000366.
[5] SCHRAG M，YOUN T，SCHINDLER J，et al. Intravenous fibrinolytic therapy in central retinal artery occlusion：a patient-level meta-analysis[J]. JAMA Neurol，2015，72（10）：1148-1154.
[6] PAGE P S，KHATTAR N K，WHITE A C，et al. Intra-arterial thrombolysis for acute central retinal artery occlusion：a systematic review and meta-analysis[J/OL]. Front Neurol，2018，9：76[2023-11-30].
https://doi.org/10.3389/fneur.2018.00076.
[7] BIAGETTI B，SIMÒ R. Pituitary apoplexy：risk factors and underlying molecular mechanisms
[J/OL]. Int J Mol Sci，2022，23（15）：8721[2023-11-30].
https://doi.org/10.3390/ijms23158721.
[8] DONEGAN D，ERICKSON D. Revisiting pituitary apoplexy[J/OL]. J Endocr Soc，2022，6（9）：bvac113
[2023-11-30]. https://doi.org/10.1210/jendso/bvac113.
[9] RAJASEKARAN S，VANDERPUMP M，BALDEWEG S，et al. UK guidelines for the management of pituitary apoplexy[J]. Clin Endocrinol（Oxf），2011，74（1）：9-20.
[10] ZAIDI H A，COTE D J，BURKE W T，et al. Time course of symptomatic recovery after endoscopic transsphenoidal surgery for pituitary adenoma apoplexy in the modern era[J/OL]. World Neurosurg，2016，96：434-439[2023-11-30]. https://doi.org/10.1016/j.wneu.2016.09.052.
[11] CIOFALO A，GULOTTA G，IANNELLA G，et al. Giant cell arteritis（GCA）：pathogenesis，clinical aspects and treatment approaches[J]. Curr Rheumatol Rev，2019，15（4）：259-268.
[12] HAYREH S S. Giant cell arteritis：its ophthalmic manifestations[J]. Indian J Ophthalmol，2021，69（2）：227-235.
[13] YOUNGER D S. Giant cell arteritis[J]. Neurol Clin，2019，37（2）：335-344.
[14] SAHONTA R，SEBASTIAN I，AARON S，et al. Eye signs in stroke[J/OL]. Ann Indian Acad Neurol，2022，25（Suppl 2）：S94-S100[2023-11-30].
https://doi.org/10.4103/aian.aian_157_22.
[15] PULA J H，YUEN C A. Eyes and stroke：the visual aspects of cerebrovascular disease[J]. Stroke Vasc Neurol，2017，2（4）：210-220.
[16] RÄTY S，SILVENNOINEN K，TATLISUMAK T. Prehospital pathways of occipital stroke patients with mainly visual symptoms[J]. Acta Neurol Scand，2018，137（1）：51-58.
[17] SALERNO A，STRAMBO D，NANNONI S，et al. Patterns of ischemic posterior circulation strokes：a clinical，anatomical，and radiological review[J]. Int J Stroke，2022，17（7）：714-722.
[18] AHN S H，KIM B J，KIM Y J，et al. Patterns and outcomes of the top of the basilar artery syndrome：the role of the posterior communicating artery[J]. Cerebrovasc Dis，2018，46（3/4）：108-117.
[19] ALEMSEGED F，NGUYEN T N，ALVERNE F M，et al. Endovascular therapy for basilar artery occlusion[J]. Stroke，2023，54（4）：1127-1137.
[20] YAMAZAKI N，KIMURA N，DOIJIRI R，et al. A low score on the National Institutes of Health Stroke scale with eye movement disorder may indicate a good candidate for acute mechanical thrombectomy for posterior circulation large vessel occlusion：illustrative cases[J/OL]. J Neurosurg Case Lessons，2022，4（5）：CASE2299
[2023-11-30]. https://doi.org/10.3171/CASE2299.
[21] SABBEN C，CHARBONNEAU F，DELVOYE F，et al. Endovascular therapy or medical management alone for isolated posterior cerebral artery occlusion：a multicenter study[J]. Stroke，2023，54（4）：928-937.
[22] ROWE F J，WRIGHT D，BRAND D，et al. A prospective profile of visual field loss following stroke：prevalence，type，rehabilitation，and outcome[J/OL]. Biomed Res Int，2013，2013：719096[2023-11-30]. https://doi.org/10.1155/2013/719096.
[23] 霍燕，蔺雪梅，吴松笛. 逆行跨突触变性视神经病变的研究进展[J]. 中华眼底病杂志，2022，38（12）：1035-1038.
HUO Y，LIN X M，WU S D. Advances in transsynaptic retrograde degeneration of optic neuropathy[J]. Chin J Ocul Fundus Dis，2022，38（12）：1035-1038.
[24] CLARENCON F，BARONNET F，SHOTAR E，et al. Should posterior cerebral artery occlusions be recanalized? Insights from the Trevo registry[J]. Eur J Neurol，2020，27（5）：787-792.
[25] MEYER L，STRACKE C P，JUNGI N，et al. Thrombectomy for primary distal posterior cerebral artery occlusion stroke：the topmost study[J]. JAMA Neurol，2021，78（4）：434-444.
[26] DAGGUBATI L C，LIU K C. Intracranial venous sinus stenting：a review of idiopathic intracranial hypertension and expanding indications
[J/OL]. Cureus，2019，11（2）：e4008[2023-11-30].
https://doi.org/10.7759/cureus.4008.
[27] BOUFFARD M A. Fulminant idiopathic intracranial hypertension[J/OL]. Curr Neurol Neurosci Rep，2020，20（4）：8[2023-11-30]. https://doi.org/10.1007/s11910-020-1026-8.
[28] THAMBISETTY M，LAVIN P J，NEWMAN N J，et al. Fulminant idiopathic intracranial hypertension[J]. Neurology，2007，68（3）：229-232.
[29] TOSCANO S，LO FERMO S，REGGIO E，et al. An update on idiopathic intracranial hypertension in adults：a look at pathophysiology，diagnostic approach and management[J]. J Neurol，2021，268（9）：3249-3268.
[30] HOREV A，BEN-ARIE G，WALTER E，et al. Emergent cerebral venous stenting：a valid treatment option for fulminant idiopathic intracranial hypertension[J/OL]. J Neurol Sci，2023，452：120761[2023-11-30]. https://doi.org/10.1016/j.jns.2023.120761.
[31] ZEHRI A H，LEE K E，KARTCHNER J，et al. Efficacy of dural venous sinus stenting in treating idiopathic intracranial hypertension with acute vision loss[J]. Neuroradiol J，2022，35（1）：86-93.
[32] 逯青丽，张咪，蔺雪梅，等. 静脉窦支架置入手术治疗暴发性特发性颅内压增高症1例[J]. 中华眼底病杂志，2023，39（4）：334-336.
LU Q L，ZHANG M，LIN X M，et al. A case of fulminant idiopathic intracranial hypertension treated by venous sinus stent implantation[J]. Chin J Ocul Fundus Dis，2023，39（4）：334-336.
[33] TAWK R G，HASAN T F，D’SOUZA C E，et al. Diagnosis and treatment of unruptured intracranial aneurysms and aneurysmal subarachnoid hemorrhage[J]. Mayo Clin Proc，2021，96（7）：1970-2000.
[34] DANDAPAT S，MENDEZ-RUIZ A，MARTÍNEZ-GALDÁMEZ M，et al. Review of current intracranial aneurysm flow diversion technology and clinical use[J]. J Neurointerv Surg，2021，13（1）：54-62.
[35] HENDERSON A D，MILLER N R. Carotid-cavernous fistula：current concepts in aetiology，investigation，and management[J]. Eye（Lond），2018，32（2）：164-172.
[36] 赵尚峰，王卫，梁熙虹，等. 海绵窦区自发性硬脑膜动静脉瘘血管内治疗研究[J]. 中国卒中杂志，2021，16（8）：828-833.
ZHAO S F，WANG W，LIANG X H，et al. Endovascular therapy for spontaneous cavernous sinus dural arteriovenous fistula[J]. Chin J Stroke，2021，16（8）：828-833.
[37] MILLER T R，GANDHI D. Intracranial dural arteriovenous fistulae：clinical presentation and management strategies[J]. Stroke，2015，46（7）：2017-2025.
[38] ROBERT T，BOTTA D，BLANC R，et al. Ocular signs caused by dural arteriovenous fistula without involvement of the cavernous sinus：a case series with review of the literature[J]. AJNR Am J Neuroradiol，2016，37（10）：1870-1875.
[39] REYNOLDS M R，LANZINO G，ZIPFEL G J. Intracranial dural arteriovenous fistulae[J]. Stroke，2017，48（5）：1424-1431.
[40] 逯青丽，蔺雪梅，刘佩，等. 表现为右侧红眼的左侧枕部硬脑膜动静脉瘘1例[J]. 中华眼科杂志，2023，59（4）：310-312.
LU Q L，LIN X M，LIU P，et al. Left occipital dural arteriovenous fistulas presenting as right red eye：a case report[J]. Chin J Ophthalmol，2023，59（4）：310-312.
[41] 《神经血管疾病复合手术规范专家共识》编写委员会. 神经血管疾病复合手术规范专家共识[J]. 中华医学杂志，2017，97（11）：804-809.
The Working Group of Expert Consensus on Neurovascular Disease Hybrid Operation Norms. Expert consensus on neurovascular disease hybrid operation norms[J]. Natl Med J China，2017，97（11）：804-809.
[42] DEBETTE S，LEYS D. Cervical-artery dissections：predisposing factors，diagnosis，and outcome[J]. Lancet Neurol，2009，8（7）：668-678.
[43] FAROUK M，SATO K，MATSUMOTO Y，et al. Endovascular treatment of internal carotid artery dissection presenting with acute ischemic stroke[J/OL]. J Stroke Cerebrovasc Dis，2020，29（3）：104592[2023-11-30]. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.104592.
[44] KESER Z，CHIANG C C，BENSON J C，et al. Cervical artery dissections：etiopathogenesis and management[J/OL]. Vasc Health Risk Manag，2022，18：685-700[2023-11-30]. https://doi.org/10.2147/VHRM.S362844.
[45] 蔺雪梅，宋金鑫，高逸飞，等. 颈内动脉夹层后视力下降1例[J]. 中国卒中杂志，2018，13（6）：616-621.
LIN X M，SONG J X，GAO Y F，et al. A case report on visual deterioration due to internal carotid artery dissection[J]. Chin J Stroke，2018，13（6）：616-621.
[46] MARKUS H S，LEVI C，KING A，et al. Antiplatelet therapy vs. anticoagulation therapy in cervical artery dissection：the cervical artery dissection in stroke study（CADISS）randomized clinical trial final results[J]. JAMA Neurol，2019，76（6）：657-664.
[47] MARNAT G，LAPERGUE B，SIBON I，et al. Safety and outcome of carotid dissection stenting during the treatment of tandem occlusions：a pooled analysis of TITAN and ETIS[J]. Stroke，2020，51（12）：3713-3718.
[48] BONTINIS V，ANTONOPOULOS C N，BONTINIS A，et al. A systematic review and meta-analysis of carotid artery stenting for the treatment of cervical carotid artery dissection[J]. Eur J Vasc Endovasc Surg，2022，64（4）：299-308.
[49] ULIVI L，SQUITIERI M，COHEN H，et al. Cerebral venous thrombosis：a practical guide[J]. Pract Neurol，2020，20（5）：356-367.
[50] FERRO J M，AGUIAR DE SOUSA D. Cerebral venous thrombosis：an update[J/OL]. Curr Neurol Neurosci Rep，2019，19（10）：74[2023-11-30].
https://doi.org/10.1007/s11910-019-0988-x.
[51] YANG Q，DUAN J G，FAN Z Y，et al. Early detection and quantification of cerebral venous thrombosis by magnetic resonance black-blood thrombus imaging[J]. Stroke，2016，47（2）：404-409.
[52] NEPAL G，KHAREL S，BHAGAT R，et al. Safety and efficacy of direct oral anticoagulants in cerebral venous thrombosis：a meta-analysis[J]. Acta Neurol Scand，2022，145（1）：10-23.
[53] GOYAL M，FLADT J，COUTINHO J M，et al. Endovascular treatment for cerebral venous thrombosis：current status，challenges，and opportunities[J]. J Neurointerv Surg，2022，14（8）：788-793.
[54] FUGATE J E，RABINSTEIN A A. Posterior reversible encephalopathy syndrome：clinical and radiological manifestations，pathophysiology，and outstanding questions[J]. Lancet Neurol，2015，14（9）：914-925.
[55] OLLIVIER M，BERTRAND A，CLARENÇON F，et al. Neuroimaging features in posterior reversible encephalopathy syndrome：a pictorial review
[J/OL]. J Neurol Sci，2017，373：188-200[2023-11-30].
https://doi.org/10.1016/j.jns.2016.12.007.
[56] HINDUJA A. Posterior reversible encephalopathy syndrome：clinical features and outcome[J/OL]. Front Neurol，2020，11：71[2023-11-30]. https://doi.org/10.3389/fneur.2020.00071.